Protein Expression Systems Market – Insights
Protein expression has become an important laboratory technology in biochemistry, molecular biology, and protein research as well as other scientific research fields, which require functional proteins for their research. The technology can also provide substrates or enzymes required for further analysis. Many chemically competent bacterial cells such as E. coli cells, suitable for protein expression and transformation, are available as research kits. Other commonly used protein expression systems include cell systems derived from insect, plants, yeast, and mammalian cells.
The global protein expression systems market size was valued at US$ 1.2 billion in 2017, and is expected to witness a CAGR of 11.1% over the forecast period (2018 – 2026).
Global Protein Expression Systems Market Revenue (US$ Mn) Analysis, By Expression Systems, 2017
Source: Coherent Market Insights Analysis (2018)
Increasing demand for protein therapeutics is expected to drive the protein expression systems market revenue
Rising incidence of various diseases such as cancer, cardiovascular conditions, and genetic disorders is the major factor driving growth of protein expression system market. For instance, protein-based drugs such as insulin, can treat a wide variety of conditions with remarkable effectiveness. Moreover, high efficiency of protein therapeutics and minimum risk of side effects associated with protein therapeutics is attracting manufacturers to invest in the protein expression systems research and development. Recombinant proteins such as enzymes and biologics are useful in the biopharmaceutical, chemical, and food industries.
Furthermore, advances in protein-engineering technologies allow drug developers and manufacturers to modify and develop desirable functional characteristics of proteins of interest while maintaining product efficacy and safety. For instance, in 2017, HumanZyme Inc., a leading supplier of novel recombinant human proteins and growth factors expressed in human cells, announced the launch of HumanKine(r) Interferon gamma (IFN gamma) expressed from HEK293 cells. IFN gamma protects against bacterial, viral, and protozoan infections.
Protein Expression Systems Market Restraints
Despite tremendous application of protein therapeutics in R&D and drug development, in some cases, the production of recombinant proteins can be expensive, complex, and time-consuming. Moreover, the recombinant proteins produced in cells may not be the same as the natural forms, therefore the difference can reduce effectiveness of therapeutic recombinant proteins and even cause side effects.
Protein Expression Systems Market - Regional Insights
On the basis of region, the global protein expression systems market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America protein expression systems market is expected to generate significant revenue share during the forecast period, owing to increasing biopharmaceutical research and development investment and activities from public and private organizations. For instance, according to Pharmaceutical Research and Manufacturers of America (PhRMA), 2016, member companies invested around US$ 58.8 billion in research and development in 2015, of which, majority was by all biopharmaceutical companies in the U.S.
Asia Pacific protein expression systems market is anticipated to grow at highest CAGR during the forecast period. The lucrative growth in the region is majorly attributed to rising interests of regional manufacturers in protein therapeutics. For instance, in 2016, Takeda Pharmaceutical and Crescendo Biologics collaborated and license agreement for the discovery, development and commercialization of Humabody-based therapeutics for cancers with a high unmet medical need. Humabodies are a novel class of extremely small, robust, and potent protein therapeutics.
Global Protein Expression Systems Market Value (US$ Mn) & Y-o-Y Growth (%)
Source: Coherent Market Insights Analysis (2018)
Protein Expression Systems Market - Competitive Landscape
Key players operating in the global protein expression systems market include Agilent Technologies, Inc., Becton, Dickinson & Company, Lonza Group Ltd., GenScript Biotech Corporation, Bio-Rad Laboratories, Inc., Merck KGaA, QIAGEN N.V., Thermo Fisher Scientific Inc., Takara Bio Inc., Synthetic Genomics Inc., Lucigen Corporation, Promega Corporation, ARTES Biotechnology GmbH, ProteoGenix, Addgene Inc., Geneva Biotech, Profacgen, and Peak Proteins Ltd.
Protein expression is an integral tool in biological research and it is gaining significant traction as a pharmaceutical production mechanism for biological therapeutics. The biotechnology industry uses both cell types prokaryotic (bacteria) and eukaryotic (animal, fungi, and plant) to synthesize recombinant proteins. The choice of the host cell depends on the protein expressed. The demand for recombinant proteins has increased as more applications in several fields are commercially available. Recombinant proteins have been utilized as tools for cellular and molecular biology.
The demand for protein therapeutics has increased considerably, owing to increase in prevalence of chronic diseases and development of plasma-derived therapies. In recent years, proteins expression systems have gained significant traction for therapeutic applications and the number of proteins launched or approved into clinical trials has continually increased. According to the National Center for Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA) approved more than 140 recombinant therapeutic proteins for human use and several hundred are currently in development.
However, high cost associated with therapeutic proteins and stringent government regulations towards approval of protein therapies are expected to hinder market growth. For instance, in India, a vial of Avastin (Bevacizumab mostly produced by the mammalian cell expression system), a monoclonal antibody, cost between US$ 372.65 to US$ 402.46. Moreover, immunogenicity is also a major concern for all recombinant drugs, as all biotechnologically produced therapeutics may exhibit some form of immunogenicity.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.